Outcomes of Acromegaly Patients Treated with Sandostatin LAR after Surgical Excision of Pituitary Adenoma
| Autor: | Muhammad Naveed Majeed, null Sumira Kiran, null Muhammad Kaleem Iftikhar, null Ch. Arslan Ahmad, null Khawar Anwar |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Pakistan Journal Of Neurological Surgery. 26:638-645 |
| ISSN: | 2409-5567 1995-8811 |
| DOI: | 10.36552/pjns.v26i4.766 |
| Popis: | Objectives: An observational study to evaluate the outcomes of Acromegaly patients treated in the department of Neurosurgery III, Punjab Institute of Neurosciences (PINS), Lahore, Pakistan. Materials and Methods: This study was the analysis of a case series of 20 patients (mean age: 30 years) of both genders with acromegaly due to macroadenoma who had endonasal excision and postoperative treatment with Sandostatin LAR. Results: This study consisted of a total of 20 patients out of which 11 (55%) were male and 9 (45%) were female. All 20 Patients (100%) had a headache as their main symptom and 13 patients (65%) had visual field deterioration. 19 patients (95%) had complete resection of the tumor whereas 1 (5%) had a subtotal resection. After surgery and treatment growth hormone levels improved in 19 patients (95%) and remained elevated in 1 patient (5%), IGF-1 (Insulin-like growth factor – 1) levels improved in all 20 (100%) patients. Following consecutive octreotide injections vision of 11 patients (84%) out of 13 improved and in 2 (16%) patients, it remained the same as of Preoperative status whereas Headache improved in all 20 (100%) of the patients. None of the patients had any complications related to the procedure or the injection of octreotide LAR. Conclusion: Acromegaly due to macroadenoma responds well to treatment with octreotide LAR after endonasal resection in terms of hormonal levels and symptoms of the patients. It is a safe treatment with very less side effects and complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|